↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Collegium Pharmaceutical$COLL · filed: grew revenue 23.6% in FY2025 to $781MNew shipTrillion Score 506Fall Risk MediumNext year $733M–$1.2B sealedCheck ▾Close ▴
What Collegium Pharmaceutical filed
Grew revenue 23.6% in FY2025 to $781 million, operating margin 23.0% against a -3.8% median for pharmaceutical preparations, equity 18.2% of assets. Every figure links to the filing it came from on Collegium Pharmaceutical’s card. New ship: no warning signs. Trillion Score 506, #88 of 182 in its field; Fall Risk Medium (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $733M and $1.2B, an 80% range sealed on 27 Sept 2026 · receipt #e74cc0 · graded in public by the revenue in Collegium Pharmaceutical’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Collegium deploys **$50M** ASR at **2.5x revenue**, signaling management sees durable cash flow where the market sees liability overhang.
$50 million
accelerated share repurchase program
$1.1 billion
making this ASR roughly
4.5%
of float—a non-trivial commitment for a company that historically…
$440 million
with operating cash flow approaching
Collegium Pharmaceutical announced a $50 million accelerated share repurchase program, the first meaningful capital return in the company's history as a public entity. The program launches immediately with an unnamed investment bank counterparty and will retire shares over the next several months. At Friday's close, Collegium carried a market capitalization near $1.1 billion, making this ASR roughly 4.5% of float—a non-trivial commitment for a company that historically reinvested every dollar into commercial infrastructure and abuse-deterrent formulation patents.
Collegium has spent the past seven years building a commercial pain portfolio anchored by Xtampza ER, its abuse-deterrent extended-release oxycodone product. Revenue for the twelve months ending September 2024 ran near $440 million, with operating cash flow approaching $120 million annually. The company carries minimal debt and closed the most recent quarter with roughly $200 million in cash and equivalents. The ASR draws from that balance sheet cushion rather than new leverage, which tells allocators the board views current valuation as sufficiently dislocated from intrinsic value to justify immediate buyback over R&D or bolt-on acquisition.
The timing matters. Collegium operates in a sector—specialty pain management—where reimbursement pressure, opioid litigation overhang, and regulatory scrutiny have compressed multiples across the board. The company trades near 2.5x trailing revenue and roughly 9x operating cash flow, multiples that reflect persistent investor skepticism toward anything touching controlled substances. Management's willingness to buyback stock at these levels signals confidence that the worst of the opioid litigation cycle has passed and that Xtampza ER's commercial trajectory remains durable despite generic competition in adjacent molecules. The ASR also preempts activist noise; $50 million returned now is cheaper than $50 million returned under external pressure six months from now.
Operators should watch Collegium's next two quarterly earnings calls for commentary on follow-on capital return. If the ASR depletes quickly and the stock remains flat, expect authorization of a second tranche or introduction of a regular dividend by mid-2025. Also monitor DEA production quota adjustments for Schedule II opioids, which directly govern Xtampza's manufacturing capacity. Any tightening of quotas would force Collegium to either ration product or seek quota transfers, both of which compress margin. Finally, track patent expiry calendars: Collegium's abuse-deterrent formulation patents extend through 2029, but generic filers often challenge early. Any Paragraph IV certification filing will reset the buyback calculus overnight.
Collegium's ASR is a bet that the market has overpenalized a profitable, cash-generative business for sins committed by others in the opioid supply chain. The $50 million is a down payment on that thesis, not a one-time gesture.
Branded by POPS4 · proof in 60 seconds
For the principal
ASR at these multiples implies management confidence in litigation tail risk fading; position for follow-on return by Q2 2025.
For the operator
Watch DEA quota updates and Paragraph IV filings; both reset the buyback math and signal when to rotate out.
For the house
Huang Goodman maintains no position but flags this as template for other specialty pharma cash conversions under activist pressure.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
